Novavax Inc. Stock Underperforms Wednesday When Compared To Competitors

Harpoon Therapeutics Inc

Change company Symbol lookup

Select an option...

HARP Harpoon Therapeutics Inc

VIRC Virco Mfg Corp

RVLP RVL Pharmaceuticals PLC

TRGP Targa Resources Corp

RCRT Recruiter.Com Group Inc

VGAS Verde Clean Fuels Inc

DHHC DiamondHead Holdings Corp

EJH E-Home Household Service Holdings Ltd

FLGC Flora Growth Corp

HL Hecla Mining Co

Health Care : Biotechnology | Small Cap Value

Company profile

Harpoon Therapeutics, Inc. is a clinical-stage immunotherapy company. The Company is engaged in the developing a T cell engager that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. It is developing a pipeline of T cell engagers using its TriTACs, focused on the treatment of solid tumors and hematologic malignancies. It has also nominated its clinical candidate using its ProTriTAC platform, a prodrug version of its TriTAC platform, designed to expand the target space for T cell engagers and bring the benefits of TriTACs to the patients. The Company’s TriTAC product candidates include HPN328, HPN217 and HPN536. The Company’s ProTriTAC product candidate include HPN601. T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells.

Novavax Inc. Stock Underperforms Wednesday When Compared To Competitors

5:15 pm ET January 11, 2023 (MarketWatch) Print

This article was automatically generated by MarketWatch using technology from Automated Insights.

Shares of Novavax Inc. (NVAX) shed 4.43% to $11.86 Wednesday, on what proved to be an all-around positive trading session for the stock market, with the NASDAQ Composite Index rising 1.76% to 10,931.67 and the Dow Jones Industrial Average rising 0.80% to 33,973.01. The stock's fall snapped a two-day winning streak. Novavax Inc. closed $123.83 short of its 52-week high ($135.69), which the company achieved on January 12th.

The stock underperformed when compared to some of its competitors Wednesday, as Johnson & Johnson (JNJ) fell 0.16% to $174.88, Pfizer Inc. (PFE) fell 0.36% to $47.45, and Merck & Co. Inc. (MRK) rose 0.23% to $111.07. Trading volume (6.0 M) remained 689,606 below its 50-day average volume of 6.7 M.

Data source: Dow Jones Market Data, FactSet. Data compiled Janurary 11, 2023.

(END) Dow Jones Newswires

January 11, 2023 17:15 ET (22:15 GMT)